{"name":"Iterion Therapeutics","slug":"iterion","ticker":"ITER","exchange":"NASDAQ","domain":"iteriontherapeutics.com","description":"Iterion Therapeutics is a biopharmaceutical company focused on the development of innovative treatments for liver diseases. The company's pipeline includes several promising candidates, including its lead asset, ITI-5001, which is being developed for the treatment of primary sclerosing cholangitis (PSC). Iterion Therapeutics is a relatively small player in the hepatology space, but its unique approach to treating liver diseases has generated significant interest among investors. The company's market position is still evolving, but it has the potential to become a major player in the industry.","hq":"Houston, TX","founded":0,"employees":"","ceo":"Glenn Mattes","sector":"Hepatology / Liver Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ITI-5001 patent cliff ($0.0B at risk)","drug":"ITI-5001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Iterion Therapeutics Announces FDA Fast Track Designation for ITI-5001","summary":"Iterion Therapeutics announced that the FDA has granted Fast Track designation to ITI-5001 for the treatment of primary sclerosing cholangitis (PSC).","drugName":"ITI-5001","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Iterion Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Iterion Therapeutics reported its third quarter 2023 financial results, which included a net loss of $13.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxQZ0pVZ1VCVFdkUFRBS3NfSmJtWGFXU3VFVlhFVnRPZURoRHBLaDFPZnA1SHBOTzVPb0RyZVQ0eGtrbGhMNllWbUJGb3Bjd21MS2dqd2pETGVaN2dOYmRmbFppOVR0bndrUDZoNlVsQzhuLU5va1dDb2ZNQVJRNmFuaU80WEcyOVJsSEFacVZ3R1Zla3lwVnBWZ0Fyck84QlNwZVFxQjZwbXd5UE45eWZPMHRSNmFnUnJxek9OSGdIREJtUE5fT1dXd1d6Q0RuMk1ucWMxXzlaQW5wcHppLUxfd2o0alNBVkJCT2NTb25nRWsyMUprbGJ0ci1sY3JiRWZGbmZrWDBnclZIM2ZBemwtQ2dXMDJ4N2RqdXJkQVZ5bnZOMzJ5WGx5UDdVcWVpeE0?oc=5","date":"2026-03-25","type":"pipeline","source":"PR Newswire","summary":"Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed - PR Newswire","headline":"Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxPTGRmUlRwYThhVldyRlRyNVZmTWMyUEpaY0dhSU10RFNLa0FQbUY4dEF5YXJNa0Q0NjBQSENqRkZ2c0JXNUJ4WU1wUk8xTXp5R2pWUDB3bmZvalVBR09ENTVHbno0Ql9hUGdpNl9vdHN2RlQ0eFlxN2VKZ09PUENnb3B0SmJCMFI2aEdqejBpNzlnU3hxM0ZrTkZMT3dHTHJVRTJVbHA0bVRVbGJXQ1FFeW1pbjlhTGpBeEZqdU1zVElscU5uUC1aLXNRRjNNZ1pLMEV3STU2VmVyX05TVF8xQ0l1T1lxbWt6SkFicjlEVkVKWU04ZXVHYlRHc0I5RDE1cTFvTUJpMEFaRnItRlM1R0hLN3BZMDZCRkdRdUk1SW1lZUg1QWxpUlBVd0xZMllEYkg1WnNSRQ?oc=5","date":"2026-02-10","type":"trial","source":"PR Newswire","summary":"Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma - PR Newswire","headline":"Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhib","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-02-20","type":"trial","source":"PR Newswire","summary":"Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments - PR N","headline":"Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxQMlRDVWxaLWJxWUVoTFBvRUV0Wml2SENkZE9NSnBvczlNR2FIV29iWFRpdW5IRWdwcjJIeDBCNTBkbUxUZERqN2ZYcDRpLS1CVUNwU2FYd1hIc3oyRE5HeW45RW9PYkpTNWxVbm9mOFpmTmktbnhTRUhhNXR5aTBYSE4zREZFUVNWNTJZVnVFZWxKZzRtdVNZb3I2RHFSajlqcEFVMWNYYjRzSkQ1SU5KYmtrbU1nQXZpd1hNVTd1WFV6MmUwMWtxSWJ1a3QzVEF4cWdzaXlGT0VwYm5HbXgyRS1YTTdpMVpLWE1OaTVBeHVjNFF1R3Y1aXBZNlhMb1RhbmJBS0taNUstMGxHZG12aDgyRzF3VU43ZnFvNk1kN2VZYzFaUkV5M1lZckZXOWlzNnVtRktvLVFzMFh1SWNfQ0kyN3FMNlU5bzV0eA?oc=5","date":"2023-05-16","type":"trial","source":"PR Newswire","summary":"Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas - PR Newswire","headline":"Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPWWFyRHRCLWwwMjlXaXlnMVlRTEVGd1RQNEc5SUJCTnBsLVRoUjZCNlZHcDF5M1ZRTGhOSFJoQ2RqS1huMFhnRWlwQjEybzhpR21zcjFCVE51cHdubDNIckdtM1ZXbEttSDdlRWdXNUlHMWtWSVhrV0JPcnRUM1lXdW5OaEZLX09jaGhtUXpkUkYycVYzSGU1VGZaR1Z0UWRWZm1sek8zRjFVVkV1c1VSU3VuNGZTVVZJSWhLd0R5QUFucGZtQzRKT0NjMUl4V016Vm5iakpNdkY3OHM3eXhENW1nM21fRFNoZTBrQzhnZnk0VWFuMTNWYS0taEpPdFRkdXZnZWpFQm5nZGpiZTA3N1JWRjJ2a2FYbmpiM1dCeDlCNnJjaDhmOVMxbUZ6bW1xaTdB?oc=5","date":"2022-06-01","type":"trial","source":"PR Newswire","summary":"Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting - PR Newswire","headline":"Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presente","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPRUh6T0x6QWdKRUkwVUF1UExNSjVzZ3NWLWJUZ1JOMjJCSllWWVBUSWdQcU94U1h6b0pXT3h5aVBmdldvQ2Q0NGxLTlBkQk1aOTZ6Z2Z5Wk91ajdlSG5vbEFIQzZvVzQ4alJfM3ZUQm52SFVBZmVsV1A3RVZBcUxpdzJxNzZXR0M4eHM4T1hmUzNjVE9CWkJ5ZXlSLWY4WlhvRVBxdjBwLUc3WTAzU25XVnpGZnUySVY2OHNiMm1wZFE2MWlfUFpwZXJCRnNPc0ZrNHc2VnZveVBGd1B2SVBrc1IzS2dPR3hGX0V2U3M2dlFnOUxtR0lySzZKUFh4TF93MnFtU09Tcmp0aVVJdkV2Uw?oc=5","date":"2022-04-08","type":"pipeline","source":"PR Newswire","summary":"Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting - PR Newswire","headline":"Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQcnZPdk96TS1GWmRPZDZXbHdBSHpfUmVQX2RGN3YxMVZXSUpFUFcwdGE4Z3BsWnFaVDlGZVNhOFg4Wmw0OWNGZTBncW0xX3RFeUJwdmtOdTRoWjY3UmhBdUx6VmtyZXRtVmVfTmphRFowaU5Gc0dYTWE0TWtDaE9QV1AyemlkTTV4cUZnWEx5WjlXMFM1c3ZTWGlacldScjVBX0hVTjM2alNIWEpoOWh0ak9PSldDdWNTeU5BY1JYd21CU1VHWExXQndORERzV0E5cGZzeDA1WGlEUmZMY0RNOGhrT0J1TFZmZlBNUzJVOVVlOTNzbTRVM2psSFJRU1Qxb3ljclRpRDhQbDVFY0p4VVNJZHRxM3RpcC1RYmViTFJxblhlcjEwVlFR?oc=5","date":"2021-04-13","type":"trial","source":"PR Newswire","summary":"Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors - PR Newswire","headline":"Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNUFpBbTh0clBlVkVLbXVNSHJxX1gyVXZDTmFhLU42VTNYRVB3VGZVTFc4T1JrbE56bEJ2bURZZUlfRnJELTdrd3BoU3F5ZjJldzJHTFhwcWtoaHgyLS1XZERnY1lHUnUxZW5VZEhVN3JwbTVnc0pERFZFSzU4UUE4VU1KN2pKVU1adUVyN3RtVGNwZlZGQTZaNEx0Rm9OTm9yTFhZS3VLTUg1Nmk4cmYxZXdHc1FSSG9JSnp6bGxsOUdWa25Xcld2aVBKOXdTS2pVb3NrQ0JnRUtrMFJLcmNqTU8xRDVjOTJ5NlZQVkR0Tno?oc=5","date":"2021-02-16","type":"pipeline","source":"PR Newswire","summary":"Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PR Newswire","headline":"Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings","sentiment":"neutral"}],"patents":[{"drugName":"ITI-5001","drugSlug":"iti-5001","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Bayer AG","AbbVie Inc."],"therapeuticFocus":["Liver Diseases","Primary Sclerosing Cholangitis (PSC)"],"financials":null,"yahoo":null}